The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

I.V. Kolyadina

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

L.É. Zavalishina

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

I.P. Ganshina

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

Yu.Yu. Andreeva

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

G.A. Frank

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

O.O. Gordeeva

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

L.G. Zhukova

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina", Moskva

A.A. Meshcheryakov

Educational and Research Medical Center of Presidential Administration of the Russian Federation, Moscow

Савелов Н. А.

E.A. Tuzova

Moscow City Oncology Hospital #62, Moscow Healthcare Department, Moscow, Russia

D.A. Morozov

Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo Roszdrava, NII fundamental'noĭ i klinicheskoĭ uronefrologii Saratovskogo GMU

I.V. Poddubnaia

Kafedra onkologii RMAPO, Moskva

Role of clustered amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II—III breast cancer

Authors:

I.V. Kolyadina, L.É. Zavalishina, I.P. Ganshina, Yu.Yu. Andreeva, G.A. Frank, O.O. Gordeeva, L.G. Zhukova, A.A. Meshcheryakov, E.A. Tuzova, D.A. Morozov, I.V. Poddubnaia

More about the authors

Views: 1900

Downloaded: 36


To cite this article:

Kolyadina IV, Zavalishina LÉ, Ganshina IP, Andreeva YuYu, Frank GA, Gordeeva OO, Zhukova LG, Meshcheryakov AA, Tuzova EA, Morozov DA, Poddubnaia IV. Role of clustered amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II—III breast cancer. Russian Journal of Archive of Pathology. 2019;81(6):56‑62. (In Russ., In Engl.)
https://doi.org/10.17116/patol20198106156

Recommended articles:
Cost-effectiveness analysis of tala­zoparib and olaparib for breast cancer in adults. Medi­cal Technologies. Asse­ssment and Choice. 2023;(1):89-98
Quality of life in breast cancer patients after imme­diate two-stage reco­nstruction. Plastic Surgery and Aesthetic Medi­cine. 2023;(2):47-53
Comprehensive analysis of the effi­cacy of personalized reha­bilitation programs in patients with breast cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2023;(2):31-38
Cardiac moni­toring of neoadjuvant chemotherapy in a patient with breast cancer. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(3):309-312

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.